Alkermes PLC (NASDAQ:ALKS) received a $78.00 target price from investment analysts at J P Morgan Chase & Co in a research note issued to investors on Friday, October 27th. The brokerage currently has a “buy” rating on the stock. J P Morgan Chase & Co’s target price indicates a potential upside of 63.01% from the company’s previous close.
ALKS has been the topic of several other research reports. UBS AG set a $54.00 target price on shares of Alkermes PLC and gave the company a “hold” rating in a research report on Friday, October 27th. Credit Suisse Group dropped their target price on shares of Alkermes PLC from $70.00 to $66.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. Barclays PLC set a $50.00 price target on shares of Alkermes PLC and gave the stock a “hold” rating in a research note on Thursday, October 26th. Citigroup Inc. set a $62.00 price target on shares of Alkermes PLC and gave the stock a “hold” rating in a research note on Thursday, October 26th. Finally, ValuEngine downgraded shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $63.55.
Shares of Alkermes PLC (NASDAQ ALKS) traded down $0.20 during trading on Friday, hitting $47.85. 1,285,300 shares of the company traded hands, compared to its average volume of 1,069,902. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.05 and a quick ratio of 2.72. Alkermes PLC has a 12-month low of $46.80 and a 12-month high of $63.40.
Alkermes PLC (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. The company had revenue of $217.40 million for the quarter, compared to analyst estimates of $231.29 million. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.27%. The firm’s revenue was up 20.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.09) earnings per share. equities analysts anticipate that Alkermes PLC will post -0.59 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2017/11/13/j-p-morgan-chase-co-analysts-give-alkermes-plc-alks-a-78-00-price-target.html.
In related news, SVP James M. Frates sold 20,932 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $47.58, for a total value of $995,944.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Kathryn L. Biberstein sold 13,566 shares of the company’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $51.29, for a total transaction of $695,800.14. Following the completion of the sale, the chief accounting officer now owns 70,455 shares of the company’s stock, valued at approximately $3,613,636.95. The disclosure for this sale can be found here. In the last 90 days, insiders sold 102,498 shares of company stock valued at $5,018,010. Company insiders own 5.34% of the company’s stock.
Several large investors have recently bought and sold shares of ALKS. Russell Investments Group Ltd. grew its stake in shares of Alkermes PLC by 23.6% during the 1st quarter. Russell Investments Group Ltd. now owns 9,835 shares of the company’s stock worth $575,000 after purchasing an additional 1,877 shares during the period. Teachers Advisors LLC grew its stake in shares of Alkermes PLC by 11.8% during the 1st quarter. Teachers Advisors LLC now owns 155,311 shares of the company’s stock worth $9,086,000 after purchasing an additional 16,354 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Alkermes PLC by 0.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 7,104 shares of the company’s stock worth $415,000 after purchasing an additional 42 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Alkermes PLC by 1.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 194,531 shares of the company’s stock worth $11,381,000 after purchasing an additional 2,891 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Alkermes PLC in the 1st quarter valued at about $7,306,000. 98.19% of the stock is currently owned by institutional investors and hedge funds.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.